No Data
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company has not yet made any plans for gene therapy.
On February 18, Glonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company currently does not have any plans for gene therapy.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Looks Inexpensive But Perhaps Not Attractive Enough
Zhejiang Jingxin Pharmaceutical (002020.SZ) has spent 0.124 billion yuan to repurchase 1.17% of its shares.
Zhejiang Jingxin Pharmaceutical (002020.SZ) issued an announcement that as of January 31, 2025, the company will continue its share repurchase...
Express News | Zhejiang Jingxin Pharmaceutical Says to Buy Back up to 400 Mln Yuan Worth of Shares in 12 Months
Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.
Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
Zhejiang Jingxin Pharmaceutical (002020.SZ): Plans to spend 0.2 billion to -0.4 billion yuan to repurchase company shares.
On January 8, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that the company would use its own funds to repurchase shares through centralized bidding. The repurchased shares will be used for Stock-based Incentive or employee stock ownership plans. The total amount of the repurchase will not be less than 0.2 billion yuan (inclusive) and not more than 0.4 billion yuan (inclusive), with the repurchase price not exceeding 14.8 yuan per share (inclusive). If calculated based on the upper and lower limits of the total repurchase amount and the upper limit of the repurchase share price, the estimated number of shares to be repurchased is approximately 13.51 million to -27.03 million shares, accounting for about 1.57% to 3.14% of the company's current total equity.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
